SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SRPT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act immediately. The stock has some positive catalyst support from FDA acceptance of the supplemental NDAs for Amondys 45 and Vyondys 53, but the overall setup is mixed: hedge funds are aggressively selling, analysts remain cautious, the stock is overbought, and the long-term fundamental picture is still clouded by regulatory and execution risk. Based on the current data, I would not buy now; I would wait for a clearer pullback or stronger fundamental confirmation.
Trend is positive in the very short term but stretched. MACD histogram is 0.395 and expanding above zero, which supports bullish momentum. However, RSI_6 is 80.024, indicating the stock is overbought after the recent move. Moving averages are converging, which suggests the trend is not yet firmly established. Price is near resistance at R1 19.039 and just below R2 19.929, while pivot support sits at 17.599. In short, momentum is constructive, but the current level is not an attractive entry for a beginner seeking a long-term position.
FDA accepted the supplemental NDAs for Amondys 45 and Vyondys 53, with a target action date of February 28, 2027, which removes near-term administrative risk and creates a clear catalyst. News flow also reflects continued regulatory engagement and talent retention efforts through RSU grants. The recent momentum in the stock and positive MACD trend also support near-term upside potential.
Hedge funds are selling aggressively, with selling up 12,693.27% over the last quarter, which is a major negative signal. Analysts remain cautious, including Sell and In Line ratings, and one major bearish view argues the FDA acceptance is not true regulatory momentum. RSI is overbought, so the recent rally may be extended. News also references a prior failed trial and a 20% drop, underscoring ongoing event risk.
No usable latest-quarter financial snapshot was provided because the financial snapshot returned an error. As a result, I cannot confirm revenue or earnings growth trends for the latest quarter season from the data available here.
Analyst tone is cautious to bearish. H.C. Wainwright reiterated a Sell rating with a $5 target on 2026-07-01, while Evercore ISI lowered its target to $19 and kept an In Line rating on 2026-05-15. RBC previously raised its target to $19 and kept Sector Perform. Overall, Wall Street appears split, but the recent trend is not bullish: the pros see a defined regulatory catalyst, while the cons emphasize failed efficacy data, limited upside, and downside risk to the core U.S. franchise.
